Skip to main content

Table 2 Analysis of the influencing factors of pregnancy, neonatal complications and child death

From: Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis

Characteristic   Pregnancy/fetal 95%CI P New born complication 95%CI P Child deaths 95%CI P
Yes No OR Yes No OR Yes No OR
Age (years)  > 30 10 3 0.95 0.125–7.275 1 10 3 7.78 1.2–50.424 0.04 3 7 3 0.248–36.325 0.588
 ≤ 30 7 2 3 7 1 7
Tumor stage IV 10 2 3.33 0.319–34.830 0.538 7 5 2.1 0.251–17.594 0.62 2 9 NA NA 1
I–III 3 2 2 3 0 4
Exposed gestational stage 1st trim 0 2 NA NA 0.043 0 2 NA NA 0.178 0 2 NA NA 1
others 17 3 13 8 2 14
Trastuzumab schedule 3 weeks 15 4 1.88 0.134–26.320 1 11 9 0.61 0.047–7.882 1 4 12 NA NA 1
1 week 2 1 2 1 0 2
Exposed time (weeks)  ≤ 12 5 2 0.63 0.079–4.959 1 2 5 0.18 0.026–1.279 0.169 0 4 NA NA 0.524
 > 12 12 3 11 5 4 10
Total dose (mg)  ≤ 3000 2 3 NA NA 0.061 1 4 0.13 0.008–1.998 0.242 0 2 NA NA 1
 > 3000 6 0 4 2 1 5
Chemotherapy Yes 5 1 1.67 0.147–18.874 1 3 3 0.7 0.108–4.538 1 0 4 NA NA 0.524
No 12 4 10 7 4 10
Endocrine therapy Yes 2 0 NA NA 1 3 0 NA NA 0.526 2 1 13 0.771–219.107 0.108
No 15 5 12 8 2 13
  1. 1st trim. the first trimester, NA not applicable